Literature DB >> 9221809

Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression.

L Beviglia1, K Matsumoto, C S Lin, B L Ziober, R H Kramer.   

Abstract

Hepatocyte growth factor/scatter factor (HGF/SF) induces cell motility and tissue remodeling of various epithelial cells through its receptor, the product of the proto-oncogene c-met. High levels of HGF/SF have been correlated with poor prognosis in human breast carcinoma. In this study, we examined the expression of the c-Met receptor in human breast-carcinoma cells in vivo and in cultured cell lines. Immunohistochemical analysis of biopsy samples of human breast carcinoma indicated that, in normal mammary gland, c-Met is localized in the ductal epithelium. The level of expression of c-Met in primary carcinomas was maintained in autologous metastatic lymph-node lesions in some cases, and in other cases was elevated. Frequently there was evidence of heterogeneity in cellular expression of c-Met within individual tumors, suggesting that micro-environmental factors may regulate receptor expression. In an analysis of a panel of human breast-carcinoma cell lines, we found that moderately differentiated cell lines did not express detectable levels of c-Met and were not responsive to HGF. In contrast, poorly differentiated and invasive cell lines did express high levels of the receptor and responded to HGF by increased motility and invasiveness. Sensitivity to HGF/SF also correlated with expression of the c-Met 9-kb mRNA. No correlation was found between gene copy number and the expression level of c-Met protein or mRNA. When the moderately differentiated and c-Met-negative T47D cell line was transfected with c-DNA for c-met, the transfectants showed delayed cell scattering and migratory response to HGF. Thus, over-expression of c-Met in moderately differentiated carcinoma cells may be one of several attributes that contribute to an invasive phenotype during the progression of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9221809     DOI: 10.1002/(sici)1097-0215(19970620)74:3<301::aid-ijc12>3.0.co;2-e

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

1.  Breast cancer associated fibroblasts promote MCF-7 invasion in vitro by secretion of HGF.

Authors:  Pingbo Chen; Qingqing Mo; Beibei Wang; Danhui Weng; Peng Wu; Gang Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

2.  α-Syntrophin is required for the hepatocyte growth factor-induced migration of cultured myoblasts.

Authors:  Min Jeong Kim; Stanley C Froehner; Marvin E Adams; Hye Sun Kim
Journal:  Exp Cell Res       Date:  2011-10-06       Impact factor: 3.905

3.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

4.  Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells.

Authors:  Sharmila Manjeshwar; Megan R Lerner; Xiao-Ping Zang; Dannielle E Branam; J Thomas Pento; Mary M Lane; Stan A Lightfoot; Daniel J Brackett; Eldon R Jupe
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

5.  Preadipocytes stimulate ductal morphogenesis and functional differentiation of human mammary epithelial cells on 3D silk scaffolds.

Authors:  Xiuli Wang; Xiaohui Zhang; Lin Sun; Balajikarthick Subramanian; Maricel V Maffini; Ana Soto; Carlos Sonnenschein; David L Kaplan
Journal:  Tissue Eng Part A       Date:  2009-10       Impact factor: 3.845

6.  Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

Authors:  Marion Zillhardt; Sun-Mi Park; Iris L Romero; Kenjiro Sawada; Anthony Montag; Thomas Krausz; S Diane Yamada; Marcus E Peter; Ernst Lengyel
Journal:  Clin Cancer Res       Date:  2011-05-06       Impact factor: 12.531

7.  MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met.

Authors:  Yue Gao; Fan Zeng; Jia-Yan Wu; Hai-Yu Li; Jian-Jun Fan; Li Mai; Ji Zhang; Dong-Mei Ma; Yun Li; Fang-zhou Song
Journal:  Tumour Biol       Date:  2014-12-10

8.  Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Authors:  Kelly L Mueller; Lauren A Hunter; Stephen P Ethier; Julie L Boerner
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch.

Authors:  Stephan C Jahn; Mary E Law; Patrick E Corsino; Nicole N Parker; Kien Pham; Bradley J Davis; Jianrong Lu; Brian K Law
Journal:  Cancer Lett       Date:  2012-08-17       Impact factor: 8.679

10.  Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study.

Authors:  Jeannette T Bensen; Chiu Kit Tse; Sarah J Nyante; Jill S Barnholtz-Sloan; Stephen R Cole; Robert C Millikan
Journal:  Cancer Causes Control       Date:  2013-03-23       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.